>>Do you have any details?>>
NovusPharma was working on two bis-platinum molecules named BBR3464 and BBR3610. The work was discontinued as there was no indication that BBR3464 would be better than drugs already market. BBR3610 was never brought into the clinic as it was felt its profile would be similar to BBR3464. On the website CTIC says the following:
Novel Platinum Compounds
We have developed two potential drug candidates, BBR 3464 and BBR 3610, that are related to the platinum-based chemotherapy agent Cisplatin. Cisplatin is one of the most widely used anti-cancer drugs and acts by binding to DNA, thereby preventing its replication and tumor cell division. However, while Cisplatin contains a single platinum atom, our compounds consist of multiple platinum atoms held together by linking molecules, allowing them to block DNA replication more effectively. This was born out by preclinical studies, which showed that BBR 3464 and BBR 3610 were far more effective than Cisplatin, in a range of solid tumors.
However, the higher efficacy of BBR 3464 was not confirmed in recent phase II studies, which yielded results that were not substantially different from Cisplatin and other platinum agents currently on the market. We now believe these disappointing results were due to the binding and degradation of the compound by human plasma proteins.
Current Research
Our current research is focused on developing new formulations and delivery systems, which could protect BBR 3464 and BBR 3610 from degradation in human plasma and allow more active drug to reach the tumor. To that end, our scientists are applying the polyglutamate technology to these molecules hoping to prevent the degradation of these molecules in the bloodstream, while targeting them directly to the tumor cells.
|
